GPR35 and colorectal carcinoma: Therefore, we sought to understand whether the GPR35 antagonist promised to be developed as an anti-CRC agent by examining the effect of GPR35 antagonist CID-2745687 (CID) (Zhao et al., 2010) on anchorage-independent cell growth and further identifying the relevant signaling pathway.